A Comparative Study of Novel Fibrosis Index and Other Non-invasive Serum Indices for Predicting Fibrosis in Patients of Chronic Liver Disease
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The Novel Fibrosis Index (NFI) effectively predicts liver fibrosis stages in Chronic Liver Disease patients. This non-invasive serum index outperformed other markers, especially for advanced fibrosis (F4 stage).
Area Of Science
- Hepatology
- Biomarkers
- Diagnostic Tools
Background
- Chronic liver disease progression leads to fibrosis and cirrhosis.
- Transient Elastography is limited by factors like ascites and obesity.
- Non-invasive serum indices offer an alternative for fibrosis staging.
Purpose Of The Study
- To compare the efficacy of various non-invasive serum indices in predicting liver fibrosis stages.
- To evaluate the performance of the Novel Fibrosis Index (NFI) against established markers.
- To identify the optimal index for staging liver fibrosis in Chronic Liver Disease.
Main Methods
- 142 Chronic Liver Disease patients were analyzed.
- Liver stiffness was measured using Transient Elastography.
- Serum indices including AST/ALT Ratio, APRI, FIB-4, and NFI were compared to fibrosis stages.
Main Results
- The Novel Fibrosis Index (NFI) demonstrated the highest Area Under the Curve for predicting fibrosis stages.
- Optimal NFI cutoffs were identified for F2, F3, and F4 stages with varying sensitivity and specificity.
- NFI showed particularly good performance in predicting advanced fibrosis (F4 stage).
Conclusions
- The Novel Fibrosis Index (NFI) is a superior non-invasive marker for predicting liver fibrosis in Chronic Liver Disease.
- NFI offers a reliable and accessible method for fibrosis staging, especially for F4.
- Further validation of NFI in diverse patient cohorts is warranted.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
